Teladoc Health, Inc. (TDOC)

From the record

Teladoc Health, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Teladoc Health, Inc.'s 6 filed years say what it did: revenue went from $1.1 billion in fiscal 2020 to $2.5 billion in fiscal 2025, up 18.3% a year; it rose in 3 of 5 years; the deepest fall was 3% from fiscal 2023 to fiscal 2025; net income was positive in 0 of 6 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Teladoc Health, Inc.'s diluted share count grew about 3.0% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 38 sales (11 under scheduled 10b5-1 plans) and 1 purchase of their own stock on the open market in the year to 2026-11-09, buying about $69 thousand (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Teladoc Health, Inc. lost about 14 cents for every dollar of shareholders' money. Leverage: it owed about 52 cents per dollar of assets, and net share issuance: its share count grew 3.3% over the year (the filed statements).

From the record

Teladoc Health, Inc.'s standing among 9 graded names in its industry family: revenue of $2.5 billion in fiscal 2025 ranks in the top 8% by size; a net margin of -7.9% ranks in the bottom 39%; revenue growth of 1.7% a year over the last 3 filed years ranks in the bottom 39% (its annual reports).

From the record

Teladoc Health, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Divita, Charles III (CHIEF EXECUTIVE OFFICER, as filed), filing under that title since 2024-06-12, 2.4 years (bottom 38% of its family); the 18 officers and directors filing in the last fifteen months have been on the record a median of 3.9 years (bottom 38%); 18 officer or director changes were reported on Form 8-K since 2023-11-13, against the 18 people in charge now (bottom 30%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Teladoc Health, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $781 million against no long-term debt tagged leaves 27.3% of its assets as net cash, top 28% of its family; cash from operations less capital spending is 11.3% of revenue (top 28%); research spending of 11% of revenue (top 50%) (its annual report).

From the record

Teladoc Health, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 1.7% a year over the last three filed years against 18.3% over all 6, slowing (bottom 31% of its family); the newest year grew -1.5% (bottom 31%); research spending grew -5.9% a year (top 50%); capital spending grew -18.6% a year (bottom 44%) (its annual reports). Teladoc Health, Inc. reported 2 product lines in fiscal 2025: Access Fees Revenue at $2.1 billion (83%), Other at $438 million (17%); 1 of 2 grew against the year before (its annual report).

From the record

Teladoc Health, Inc.'s newest year against its own record: revenue of $2.5 billion in fiscal 2025 came in 4.7% below the $2.7 billion its prior three years' pace pointed to (bottom 42% of its family); net income of $200 million against a prior three-year average of $5.0 billion (top 42%); a net margin of -7.9% against losses larger than its revenue before (top 8%) (its annual reports).